Mantle Cell Lymphoma (MCL)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

DrugDrug NameDrug Description
DB11703AcalabrutinibTo date, acalabrutinib has been used in trials studying the treatment of B-All, Myelofibrosis, Ovarian Cancer, Multiple Myeloma, and Hodgkin Lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib) medication as a Bruton Tyrosine Kinase (BTK) inhibitor indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have already received at least one prior therapy, marking the company's first entry into the treatment of blood cancers. Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib [L1009].
DB00188BortezomibBortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. The boron atom within bortezomib catalytically binds the active site of the 26S proteasome with high affinity and specificity, thereby resulting in cell cycle arrest and apoptosis. In normal cells, the proteasome is involved in degradation of ubiquitylated proteins that have been tagged for destruction because they are damaged or unneeded by the cell. However, in cancerous cells, proteasome activity degrades pro-apoptotic proteins such as p53 that would normally result in programmed cell death of the dysfunctional cells. Proteasome inhibitors such as bortezomib interrupt this process, resulting in destruction of cancerous cells. Bortezomib is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.
DB09053IbrutinibIbrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies.[A32299] Ibrutinib was developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma. Later, in February 2014, ibrutinib was approved for the treatment of chronic lymphocytic leukemia and it is also indicated for the treatment of patients with Waldenström's Macroglobulinemia.[L1926] Ibrutinib has also been approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.[A32299] Ibrutinib was approved for use in chronic graft versus host disease in August 2017 [L937].
DB00480LenalidomideLenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005.
DrugDrug NamePhaseStatusCount
DB06769Bendamustine0Recruiting1
DB00531Cyclophosphamide0Completed1
DB00997Doxorubicin0Completed1
DB09053Ibrutinib0Not Yet Recruiting1
DB09053Ibrutinib0Recruiting1
DB00563Methotrexate0Completed1
DB00811Ribavirin0Recruiting1
DB00073Rituximab0Recruiting1
DB00877Sirolimus0Completed1
DB11581Venetoclax0Recruiting1
DB00541Vincristine0Completed1
DB12001Abemaciclib1Active Not Recruiting1
DB11703Acalabrutinib1Not Yet Recruiting1
DB09312Antilymphocyte immunoglobulin (horse)1Active Not Recruiting1
DB00098Antithymocyte immunoglobulin (rabbit)1Active Not Recruiting1
DB06467Apolizumab1Terminated1
DB05015Belinostat1Completed1
DB06769Bendamustine1Active Not Recruiting1
DB06769Bendamustine1Completed2
DB06769Bendamustine1Not Yet Recruiting1
DB06769Bendamustine1Recruiting2
DB00188Bortezomib1Active Not Recruiting1
DB00188Bortezomib1Completed2
DB11666Buparlisib1Active Not Recruiting1
DB08889Carfilzomib1Completed1
DB00262Carmustine1Recruiting1
DB01413Cefepime1Completed1
DB00291Chlorambucil1Completed1
DB11646Conatumumab1Completed1
DB00987Cytarabine1Not Yet Recruiting1
DB00987Cytarabine1Recruiting2
DB11731Depatuxizumab mafodotin1Completed1
DB11714Durvalumab1Not Yet Recruiting1
DB00773Etoposide1Recruiting1
DB01590Everolimus1Completed1
DB00099Filgrastim1Active Not Recruiting1
DB00099Filgrastim1Recruiting1
DB00196Fluconazole1Recruiting1
DB01073Fludarabine1Active Not Recruiting1
DB01073Fludarabine1Completed1
DB00070Hyaluronidase1Not Yet Recruiting1
DB09053Ibrutinib1Active Not Recruiting2
DB09053Ibrutinib1Not Yet Recruiting1
DB09053Ibrutinib1Recruiting2
DB09053Ibrutinib1Withdrawn1
DB09054Idelalisib1Completed2
DB09054Idelalisib1Recruiting1
DB10791Influenza A virus A/california/7/2009 x-179a (H1N1) antigen (formaldehyde inactivated)1Recruiting1
DB00480Lenalidomide1Completed1
DB00480Lenalidomide1Not Yet Recruiting1
DB00480Lenalidomide1Recruiting1
DB01042Melphalan1Recruiting1
DB00563Methotrexate1Active Not Recruiting1
DB06650Ofatumumab1Completed1
DB00338Omeprazole1Recruiting1
DB11697Pacritinib1Not Yet Recruiting1
DB09073Palbociclib1Active Not Recruiting1
DB09073Palbociclib1Completed1
DB06603Panobinostat1Completed1
DB00019Pegfilgrastim1Recruiting1
DB05578Ramucirumab1Active Not Recruiting1
DB00912Repaglinide1Recruiting1
DB00073Rituximab1Active Not Recruiting1
DB00073Rituximab1Completed2
DB00073Rituximab1Not Yet Recruiting2
DB00073Rituximab1Recruiting3
DB00073Rituximab1Terminated1
DB05969SNS-0321Completed1
DB00864Tacrolimus1Active Not Recruiting1
DB11760Talazoparib1Completed1
DB12887Tazemetostat1Recruiting2
DB11930Varlilumab1Completed1
DB11581Venetoclax1Not Yet Recruiting1
DB11581Venetoclax1Recruiting1
DB00541Vincristine1Recruiting1
DB12400Voxtalisib1Completed1
DB09312Antilymphocyte immunoglobulin (horse)1 / 2Not Yet Recruiting1
DB00098Antithymocyte immunoglobulin (rabbit)1 / 2Not Yet Recruiting1
DB06769Bendamustine1 / 2Completed1
DB06769Bendamustine1 / 2Recruiting1
DB06769Bendamustine1 / 2Unknown Status1
DB06769Bendamustine1 / 2Withdrawn1
DB00188Bortezomib1 / 2Active Not Recruiting2
DB00188Bortezomib1 / 2Completed3
DB00188Bortezomib1 / 2Recruiting1
DB00262Carmustine1 / 2Not Yet Recruiting1
DB00493Cefotaxime1 / 2Active Not Recruiting1
DB00493Cefotaxime1 / 2Not Yet Recruiting1
DB00242Cladribine1 / 2Active Not Recruiting1
DB00631Clofarabine1 / 2Completed1
DB06189Clofarabine1 / 2Completed1
DB00531Cyclophosphamide1 / 2Active Not Recruiting1
DB00531Cyclophosphamide1 / 2Not Yet Recruiting1
DB00531Cyclophosphamide1 / 2Recruiting2
DB00531Cyclophosphamide1 / 2Withdrawn1
DB00987Cytarabine1 / 2Active Not Recruiting1
DB00987Cytarabine1 / 2Not Yet Recruiting1
DB01234Dexamethasone1 / 2Active Not Recruiting1
DB00997Doxorubicin1 / 2Active Not Recruiting1
DB12121Entospletinib1 / 2Recruiting1
DB00773Etoposide1 / 2Not Yet Recruiting1
DB01590Everolimus1 / 2Completed1
DB00099Filgrastim1 / 2Not Yet Recruiting1
DB01073Fludarabine1 / 2Not Yet Recruiting1
DB01073Fludarabine1 / 2Recruiting1
DB01073Fludarabine1 / 2Withdrawn1
DB09053Ibrutinib1 / 2Active Not Recruiting1
DB09053Ibrutinib1 / 2Recruiting6
DB09570Ixazomib1 / 2Recruiting2
DB00480Lenalidomide1 / 2Completed4
DB01042Melphalan1 / 2Not Yet Recruiting1
DB00563Methotrexate1 / 2Active Not Recruiting1
DB05764Navitoclax1 / 2Completed1
DB12191Obatoclax1 / 2Completed1
DB08935Obinutuzumab1 / 2Recruiting1
DB06650Ofatumumab1 / 2Unknown Status1
DB09037Pembrolizumab1 / 2Recruiting1
DB00073Rituximab1 / 2Active Not Recruiting2
DB00073Rituximab1 / 2Completed4
DB00073Rituximab1 / 2Not Yet Recruiting1
DB00073Rituximab1 / 2Recruiting1
DB06287Temsirolimus1 / 2Completed1
DB06287Temsirolimus1 / 2Withdrawn1
DB11850Ublituximab1 / 2Active Not Recruiting1
DB11850Ublituximab1 / 2Completed1
DB11581Venetoclax1 / 2Recruiting1
DB00541Vincristine1 / 2Active Not Recruiting1
DB00541Vincristine1 / 2Completed1
DB12001Abemaciclib2Active Not Recruiting1
DB11703Acalabrutinib2Active Not Recruiting1
DB00316Acetaminophen2Completed1
DB00316Acetaminophen2Recruiting1
DB00087Alemtuzumab2Terminated1
DB05220Alisertib2Completed1
DB00437Allopurinol2Recruiting1
DB09312Antilymphocyte immunoglobulin (horse)2Terminated1
DB00098Antithymocyte immunoglobulin (rabbit)2Completed1
DB00098Antithymocyte immunoglobulin (rabbit)2Terminated1
DB06769Bendamustine2Active Not Recruiting1
DB06769Bendamustine2Completed4
DB06769Bendamustine2Recruiting1
DB00188Bortezomib2Active Not Recruiting4
DB00188Bortezomib2Completed4
DB00188Bortezomib2Not Yet Recruiting2
DB00188Bortezomib2Recruiting1
DB00188Bortezomib2Terminated3
DB00188Bortezomib2Unknown Status1
DB01008Busulfan2Active Not Recruiting1
DB01008Busulfan2Not Yet Recruiting1
DB01008Busulfan2Recruiting1
DB04972Canfosfamide2Completed1
DB00262Carmustine2Active Not Recruiting1
DB00262Carmustine2Recruiting3
DB00262Carmustine2Unknown Status1
DB00493Cefotaxime2Not Yet Recruiting1
DB00493Cefotaxime2Recruiting3
DB00291Chlorambucil2Active Not Recruiting1
DB00291Chlorambucil2Completed1
DB00242Cladribine2Active Not Recruiting1
DB09110Coenzyme M2Active Not Recruiting1
DB09110Coenzyme M2Completed1
DB09110Coenzyme M2Recruiting1
DB12483Copanlisib2Terminated1
DB00531Cyclophosphamide2Active Not Recruiting1
DB00531Cyclophosphamide2Completed4
DB00531Cyclophosphamide2Not Yet Recruiting2
DB00531Cyclophosphamide2Recruiting7
DB00531Cyclophosphamide2Unknown Status1
DB00091Cyclosporine2Completed1
DB00091Cyclosporine2Recruiting3
DB00987Cytarabine2Active Not Recruiting3
DB00987Cytarabine2Completed1
DB00987Cytarabine2Not Yet Recruiting2
DB00987Cytarabine2Recruiting5
DB00987Cytarabine2Unknown Status1
DB09331Daratumumab2Terminated1
DB01234Dexamethasone2Active Not Recruiting1
DB01234Dexamethasone2Completed2
DB01234Dexamethasone2Not Yet Recruiting2
DB01234Dexamethasone2Recruiting2
DB01234Dexamethasone2Terminated1
DB01234Dexamethasone2Unknown Status1
DB12021Dinaciclib2Terminated1
DB01075Diphenhydramine2Completed1
DB00997Doxorubicin2Completed3
DB00997Doxorubicin2Not Yet Recruiting1
DB00997Doxorubicin2Recruiting1
DB00997Doxorubicin2Unknown Status1
DB05129Elsamitrucin2Completed1
DB06210Eltrombopag2Terminated1
DB12121Entospletinib2Active Not Recruiting1
DB12121Entospletinib2Completed1
DB06486Enzastaurin2Completed1
DB00898Ethanol2Active Not Recruiting1
DB00773Etoposide2Active Not Recruiting2
DB00773Etoposide2Recruiting4
DB00773Etoposide2Unknown Status1
DB01590Everolimus2Active Not Recruiting1
DB01590Everolimus2Completed1
DB00099Filgrastim2Active Not Recruiting1
DB00099Filgrastim2Completed2
DB00099Filgrastim2Recruiting2
DB01073Fludarabine2Active Not Recruiting2
DB01073Fludarabine2Completed1
DB01073Fludarabine2Not Yet Recruiting2
DB01073Fludarabine2Recruiting5
DB01073Fludarabine2Terminated2
DB00674Galantamine2Recruiting1
DB00441Gemcitabine2Active Not Recruiting1
DB00441Gemcitabine2Completed1
DB00889Granisetron2Completed1
DB00956Hydrocodone2Recruiting1
DB00741Hydrocortisone2Completed1
DB00557Hydroxyzine2Recruiting1
DB00078Ibritumomab tiuxetan2Completed5
DB00078Ibritumomab tiuxetan2Terminated1
DB09053Ibrutinib2Completed3
DB09053Ibrutinib2Enrolling by Invitation1
DB09053Ibrutinib2Not Yet Recruiting4
DB09053Ibrutinib2Recruiting4
DB09054Idelalisib2Completed1
DB01181Ifosfamide2Recruiting1
DB05003Imexon2Completed1
DB05707Isosorbide2Completed1
DB09570Ixazomib2Not Yet Recruiting1
DB09570Ixazomib2Recruiting1
DB00480Lenalidomide2Active Not Recruiting4
DB00480Lenalidomide2Completed4
DB00480Lenalidomide2Not Yet Recruiting1
DB00480Lenalidomide2Recruiting1
DB00650Leucovorin2Recruiting1
DB00007Leuprolide2Terminated1
DB01042Melphalan2Active Not Recruiting1
DB01042Melphalan2Completed1
DB01042Melphalan2Not Yet Recruiting1
DB01042Melphalan2Recruiting3
DB01042Melphalan2Unknown Status1
DB00563Methotrexate2Active Not Recruiting1
DB00563Methotrexate2Not Yet Recruiting1
DB00563Methotrexate2Recruiting1
DB00959Methylprednisolone2Completed1
DB01204Mitoxantrone2Completed1
DB01204Mitoxantrone2Terminated2
DB14219Monomethyl fumarate2Not Yet Recruiting1
DB00688Mycophenolate mofetil2Completed1
DB00688Mycophenolate mofetil2Not Yet Recruiting1
DB00688Mycophenolate mofetil2Recruiting6
DB08935Obinutuzumab2Recruiting3
DB06650Ofatumumab2Active Not Recruiting1
DB00526Oxaliplatin2Completed1
DB11697Pacritinib2Completed1
DB09073Palbociclib2Recruiting1
DB00252Phenytoin2Active Not Recruiting1
DB00635Prednisone2Completed1
DB10415Rabbit2Completed1
DB00073Rituximab2Active Not Recruiting9
DB00073Rituximab2Completed15
DB00073Rituximab2Not Yet Recruiting2
DB00073Rituximab2Recruiting5
DB00073Rituximab2Terminated2
DB00073Rituximab2Unknown Status2
DB00936Salicylic acid2Active Not Recruiting1
DB00020Sargramostim2Active Not Recruiting1
DB00877Sirolimus2Active Not Recruiting1
DB00877Sirolimus2Recruiting3
DB09325Sodium fluoride2Recruiting1
DB09325Sodium fluoride2Unknown Status1
DB00864Tacrolimus2Active Not Recruiting1
DB00864Tacrolimus2Not Yet Recruiting1
DB00864Tacrolimus2Recruiting2
DB00864Tacrolimus2Terminated1
DB04960Tipifarnib2Terminated1
DB00081Tositumomab2Completed2
DB02891Tricyclazole2Recruiting1
DB02891Tricyclazole2Unknown Status1
DB06334Tucidinostat2Recruiting1
DB01586Ursodeoxycholic acid2Active Not Recruiting1
DB11581Venetoclax2Not Yet Recruiting2
DB11581Venetoclax2Recruiting1
DB00541Vincristine2Completed3
DB00541Vincristine2Not Yet Recruiting1
DB00541Vincristine2Recruiting1
DB00541Vincristine2Unknown Status1
DB02546Vorinostat2Active Not Recruiting1
DB02546Vorinostat2Terminated2
DB06769Bendamustine2 / 3Recruiting1
DB01073Fludarabine2 / 3Terminated1
DB11850Ublituximab2 / 3Recruiting1
DB11703Acalabrutinib3Withdrawn1
DB06769Bendamustine3Active Not Recruiting1
DB06769Bendamustine3Completed2
DB00188Bortezomib3Active Not Recruiting1
DB00262Carmustine3Unknown Status1
DB00531Cyclophosphamide3Active Not Recruiting1
DB00531Cyclophosphamide3Completed1
DB00531Cyclophosphamide3Unknown Status1
DB00091Cyclosporine3Active Not Recruiting1
DB00091Cyclosporine3Completed1
DB00987Cytarabine3Active Not Recruiting1
DB00987Cytarabine3Unknown Status1
DB01234Dexamethasone3Active Not Recruiting1
DB01234Dexamethasone3Unknown Status1
DB12496Dihydroxyacetone phosphate3Recruiting1
DB00997Doxorubicin3Active Not Recruiting1
DB00997Doxorubicin3Completed1
DB00997Doxorubicin3Unknown Status1
DB00773Etoposide3Unknown Status1
DB01073Fludarabine3Active Not Recruiting2
DB01073Fludarabine3Completed1
DB09053Ibrutinib3Active Not Recruiting1
DB09053Ibrutinib3Completed1
DB09053Ibrutinib3Enrolling by Invitation1
DB09053Ibrutinib3Recruiting3
DB09053Ibrutinib3Withdrawn1
DB00480Lenalidomide3Active Not Recruiting1
DB00480Lenalidomide3Recruiting1
DB00480Lenalidomide3Terminated1
DB01042Melphalan3Unknown Status1
DB00688Mycophenolate mofetil3Active Not Recruiting1
DB00688Mycophenolate mofetil3Completed1
DB00019Pegfilgrastim3Unknown Status1
DB00635Prednisone3Active Not Recruiting1
DB00635Prednisone3Completed1
DB00635Prednisone3Unknown Status1
DB00073Rituximab3Active Not Recruiting3
DB00073Rituximab3Completed3
DB00073Rituximab3Recruiting4
DB00073Rituximab3Unknown Status1
DB00073Rituximab3Withdrawn1
DB00877Sirolimus3Completed1
DB06287Temsirolimus3Completed1
DB11581Venetoclax3Recruiting1
DB00541Vincristine3Active Not Recruiting1
DB00541Vincristine3Completed1
DB00541Vincristine3Unknown Status1
DB00493Cefotaxime4Recruiting1
DB00515Cisplatin4Recruiting1
DB00531Cyclophosphamide4Recruiting1
DB00987Cytarabine4Recruiting1
DB01234Dexamethasone4Recruiting1
DB00514Dextromethorphan4Recruiting1
DB00997Doxorubicin4Recruiting1
DB00773Etoposide4Recruiting1
DB12117Mitometh4Recruiting1
DB00635Prednisone4Recruiting1
DB00073Rituximab4Recruiting1
DB01041Thalidomide4Recruiting1
DB00541Vincristine4Recruiting1
DB06626AxitinibNot AvailableRecruiting1
DB00074BasiliximabNot AvailableTerminated1
DB00531CyclophosphamideNot AvailableRecruiting1
DB00531CyclophosphamideNot AvailableTerminated1
DB00091CyclosporineNot AvailableRecruiting1
DB00091CyclosporineNot AvailableTerminated1
DB01073FludarabineNot AvailableRecruiting1
DB01073FludarabineNot AvailableTerminated1
DB09053IbrutinibNot AvailableRecruiting2
DB00480LenalidomideNot AvailableNot Yet Recruiting1
DB00688Mycophenolate mofetilNot AvailableRecruiting1
DB00688Mycophenolate mofetilNot AvailableTerminated1
DB10319Streptococcus pneumoniae type 1 capsular polysaccharide antigenNot AvailableTerminated1
DB01268SunitinibNot AvailableRecruiting1
DB06287TemsirolimusNot AvailableRecruiting1
DB01041ThalidomideNot AvailableActive Not Recruiting1